Tags

Type your tag names separated by a space and hit enter

Aspirin-exacerbated respiratory disease and current treatment modalities.
Eur Arch Otorhinolaryngol. 2017 Mar; 274(3):1291-1300.EA

Abstract

Aspirin-exacerbated respiratory disease (AERD) refers to the combination of asthma, chronic rhinosinusitis with nasal polyposis, and acute upper and lower respiratory tract reactions to the ingestion of aspirin (acetylsalicylic acid, ASA) and other cyclooxygenase-1 inhibiting non-steroidal anti-inflammatory drugs. AERD affects 0.3-0.9 % of the general population. AERD generally occurs due to abnormalities in mediators and expression of arachidonic acid biosynthesis. Local IgE responses to staphylococcal enterotoxins may also be responsible for eosinophilic activation in the nasal polyp tissues of AERD patients. Clinical features of AERD include the onset of nasal congestion with anosmia, progressing to chronic pansinusitis and nasal polyps that regrow rapidly after surgery. Aspirin desensitization, Leukotriene-modifying agents, biologic agents, management of asthma, chronic rhinosinusitis, and nasal polyposis are recommended as treatment modalities. Immunotherapy is prescribed only to those AERD patients who experience clear seasonal or perennial allergy symptoms in addition to the symptoms attributable to chronic nasal polyposis. There are also investigational and dietary therapies. In this review, the important aspects of AERD will be presented, along with a literature survey.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Sakalar EG
ENT Clinics, Yunus Emre State Hospital, Eskisehir, Turkey.
Muluk NB
Department of Otorhinolaryngology, Medical Faculty, Kirikkale University, Kirikkale, Turkey. nuray.bayar@yahoo.com. , Birlik Mahallesi, Zirvekent 2. Etap Sitesi, C-3 blok, No: 6-3/43, 06610, Çankaya, Ankara, Turkey. nuray.bayar@yahoo.com.
Kar M
ENT Clinics, Kumluca State Hospital, Antalya, Turkey.
Cingi C
Department of Otorhinolaryngology, Medical Faculty, Eskisehir Osmangazi University, Eskisehir, Turkey.

MeSH

AlgorithmsAnti-Allergic AgentsAnti-Inflammatory Agents, Non-SteroidalAntibodies, Monoclonal, HumanizedAspirinAsthmaDesensitization, ImmunologicDietHumansImmunotherapyLeukotriene AntagonistsNasal PolypsOmalizumabRhinitisSalicylatesSinusitis

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

27538737

Citation

Sakalar, Emine Güven, et al. "Aspirin-exacerbated Respiratory Disease and Current Treatment Modalities." European Archives of Oto-rhino-laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated With the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, vol. 274, no. 3, 2017, pp. 1291-1300.
Sakalar EG, Muluk NB, Kar M, et al. Aspirin-exacerbated respiratory disease and current treatment modalities. Eur Arch Otorhinolaryngol. 2017;274(3):1291-1300.
Sakalar, E. G., Muluk, N. B., Kar, M., & Cingi, C. (2017). Aspirin-exacerbated respiratory disease and current treatment modalities. European Archives of Oto-rhino-laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated With the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 274(3), 1291-1300. https://doi.org/10.1007/s00405-016-4273-1
Sakalar EG, et al. Aspirin-exacerbated Respiratory Disease and Current Treatment Modalities. Eur Arch Otorhinolaryngol. 2017;274(3):1291-1300. PubMed PMID: 27538737.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Aspirin-exacerbated respiratory disease and current treatment modalities. AU - Sakalar,Emine Güven, AU - Muluk,Nuray Bayar, AU - Kar,Murat, AU - Cingi,Cemal, Y1 - 2016/08/18/ PY - 2016/07/12/received PY - 2016/08/16/accepted PY - 2016/8/20/pubmed PY - 2017/6/10/medline PY - 2016/8/20/entrez KW - Aspirin (acetylsalicylic acid, ASA) KW - Aspirin-exacerbated respiratory disease (AERD) KW - Asthma KW - Chronic rhinosinusitis with nasal polyposis KW - Cyclooxygenase-1-inhibiting non-steroidal anti-inflammatory drugs SP - 1291 EP - 1300 JF - European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery JO - Eur Arch Otorhinolaryngol VL - 274 IS - 3 N2 - Aspirin-exacerbated respiratory disease (AERD) refers to the combination of asthma, chronic rhinosinusitis with nasal polyposis, and acute upper and lower respiratory tract reactions to the ingestion of aspirin (acetylsalicylic acid, ASA) and other cyclooxygenase-1 inhibiting non-steroidal anti-inflammatory drugs. AERD affects 0.3-0.9 % of the general population. AERD generally occurs due to abnormalities in mediators and expression of arachidonic acid biosynthesis. Local IgE responses to staphylococcal enterotoxins may also be responsible for eosinophilic activation in the nasal polyp tissues of AERD patients. Clinical features of AERD include the onset of nasal congestion with anosmia, progressing to chronic pansinusitis and nasal polyps that regrow rapidly after surgery. Aspirin desensitization, Leukotriene-modifying agents, biologic agents, management of asthma, chronic rhinosinusitis, and nasal polyposis are recommended as treatment modalities. Immunotherapy is prescribed only to those AERD patients who experience clear seasonal or perennial allergy symptoms in addition to the symptoms attributable to chronic nasal polyposis. There are also investigational and dietary therapies. In this review, the important aspects of AERD will be presented, along with a literature survey. SN - 1434-4726 UR - https://www.unboundmedicine.com/medline/citation/27538737/Aspirin_exacerbated_respiratory_disease_and_current_treatment_modalities_ DB - PRIME DP - Unbound Medicine ER -